Xeris Biopharma Holdings, Inc., a commercial-stage biopharmaceutical company, engages in developing and commercializing therapies for chronic endocrine and neurological diseases in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia in pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome. It is also developing XP-8121, a once-weekly subcutaneous injection of levothyroxine that is in phase 3 clinical trial for the treatment of hypothyroidism. The company was incorporated in 2005 and is headquartered in Chicago, Illinois.

• Download SqueezeTrigger (TM) Report
• Download FrictionFactor Report
• Download Daily Short Volume Report
• Download Real-Time Short Volume Tool
• Download Failures to Deliver

• [02/27/2026 11:08 PST] Xeris Biopharma Holdings, Inc. (NASDAQ:XERS), Down By 100% ($6.61) From $6.61 After BUYINS.NET Report Predicted Stock Would Go Down Due To Bearish Conditions
• [02/23/2026 06:53 PST] XERS Expected to Trade Down Short Term
• [01/27/2026 07:08 PST] XERS Expected to Trade Up After Bullish Patterns Develop
• [01/22/2026 06:49 PST] sector Stocks Expected To Be Up After Top Correlated Stocks Fire Buy Signals.
• [01/12/2026 06:21 PST] sector Stocks Expected To Be Up After Top Correlated Stocks Fire Buy Signals.
• [01/06/2026 07:30 PST] XERS Expected to Trade Down After Bearish Patterns Develop
• [01/06/2026 06:55 PST] XERS Expected to Trade Down Short Term